関連する実験動画
Updated: Feb 17, 2026

13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.4K
コロンビアの子どもたちの尿酸と不健康な代謝現象型
Gina Gonzalez-Valencia1, Johana Hernandez2, Silvia Rueda2
1Department of Pediatric Endocrinology, School of Medicine, University of Antioquia, Medellín, Colombia. ginagv.endoped@gmail.com.
Pediatric endocrinology, diabetes, and metabolism
|February 16, 2026
まとめ
代謝的に不健康な肥満の子どもは,代謝的に健康な仲間よりも尿酸 (UA) のレベルが高くなります. 増加したUAは,小児肥満における代謝リスクのマーカーとして機能する可能性があります.
科学分野:
- 小児内分泌学について
- メタボリック・ヘルス メタボリック・ヘルス
- 公衆衛生は公衆衛生である.
背景:
- 子どもの過体重と肥満は,公衆衛生上の課題として増大しています.
- 代謝的に健康な肥満児 (MHO) と代謝的に不健康な肥満児 (MUHO) の間の差異マーカーを特定することは極めて重要です.
- 尿酸 (UA) は潜在的代謝リスクマーカーとして調査されています.
研究 の 目的:
- 体重過多または肥満の子供の尿酸 (UA) 濃度の違いを評価するために.
- 2018年のダマンフーリー基準を用いて,代謝現象型に基づいて子どもを分類する.
- UAレベルとインスリン抵抗性指数との関係を評価する.
主な方法:
- 5歳から18歳までの子供の遡及的横断研究.
- 80人の患者は,トリグリセリド,グルコース,HDL-C,血圧に基づいてMHO (n=36) とMUHO (n=44) に分類されました.
- 学生のtテストは平均UA差を分析し,インスリン抵抗性指数との相関を調べました.
主要な成果:
- MUHO (5.4 mg/dl) とMHO (4.5 mg/dl) グループ (p=0.0069) の間でUA値の統計的に有意な差異が観察されました.
- UAレベルとTyG比率 (0.4137) とTG/HDL指数 (0.3813) の間には中程度の正の相関が見られた.
結論:
- 代謝的に不健康な肥満児の尿酸濃度は,代謝的に健康な肥満児と比較して,著しく高い.
- UA濃度の上昇は,インスリン抵抗性のマーカーと相関しています.
- UAは,小児の過体重および肥満を評価するための貴重な代謝リスクマーカーとして役立つ可能性があります.
関連する概念動画
Inborn Errors of Metabolism
925
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
925
Pharmacokinetics in Pediatric Patients: Drug Metabolism
256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Overview of Protein Metabolism
4.1K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
10
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
10
Lethal Alleles
18.3K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
18.3K

